Aligos Therapeutics, Inc.

ALGS

$6.04

-2.89%

N/A-$0.18

Healthcare

Biotechnology

NASDAQ

Active Trading

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and ...

Financial Highlights of ALGS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

99.2%

Net Margin

-241.0%

P/E Ratio

-0.83x

n/a

Debt / Equity

0.11

n/a

Current Ratio

2.19

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

99.2%

Net Margin

-241.0%

P/E Ratio

-0.83x

Debt / Equity

0.11

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	100.0%	100.0%	100.0%	100.0%	57.5%	—
Operating MarginOperating income as a percentage of revenue.	-2943.8%	-701.7%	-567.5%	-2259.9%	-4024.9%	—
Net MarginNet income as a percentage of revenue.	-2944.1%	-690.6%	-564.6%	-3326.0%	-1106.7%	—
EBITDA MarginEBITDA divided by revenue.	-2854.1%	-663.4%	-539.7%	-3251.2%	-1049.8%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-2940.8%	-689.9%	-559.5%	-3317.6%	-1092.4%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	5.25	4.03	5.90	2.86	3.90	—
Quick RatioLiquid assets divided by current liabilities.	5.25	4.03	5.90	2.86	3.90	—
Cash RatioCash and equivalents divided by current liabilities.	4.80	2.46	5.68	1.70	0.86	—
Debt / AssetsDebt as a share of total assets.	6.1%	8.6%	7.4%	11.9%	5.9%	—
Debt / EquityDebt compared with shareholder equity.	0.08	0.12	0.12	-0.29	0.10	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.00x	0.00x	0.23x	—
Asset TurnoverRevenue generated per dollar of assets.	0.02x	0.09x	0.10x	0.06x	0.02x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.02x	0.10x	0.14x	0.05x	0.04x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-92.16x	-10.59x	-4.72x	-1.90x	-3.80x	—
P/B RatioPrice paid for each dollar of book value.	64.02x	9.79x	4.48x	-8.61x	1.72x	—
P/S RatioPrice paid for each dollar of sales.	2713.26x	73.13x	26.59x	63.27x	42.14x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-101.47x	-12.66x	-5.23x	-3.09x	-1.11x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

Upstream

Unnamed Small Molecule CDMOs (Multiple)AM Chemicals LLCLuxna Biotech Co., Ltd.Emory UniversityKU Leuven / Rega Institute / CD3Unnamed Clinical Research Organizations (CROs)Unnamed Raw Material/API Suppliers

Downstream

Merck & Co., Inc.NYSE:MRKXiamen Amoytop Biotech Co., Ltd.SHA:688278

Proxies

Merck & Co., Inc.NYSE:MRKXiamen Amoytop Biotech Co., Ltd.SHA:688278Madrigal Pharmaceuticals, Inc.NASDAQ:MDGL Gilead Sciences, Inc.NASDAQ:GILD

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

Aligos Therapeutics, Inc.

Financial Highlights of ALGS

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of ALGS

Upstream

Downstream

Proxies

Financial Highlights of ALGS

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of ALGS

Upstream

Downstream

Proxies